WP1: Identification of neuroactive biomarker(s) reflecting the sensitivity or resilience to psychological disturbances in AD patients
The hypothesis of WP1 is that blood metabolites with neuroactive properties can drive psychological disturbances (mood and cognitive functions). The primary objective is to perform untargeted metabolomics in order to identify blood metabolite(s) associated with psychological symptoms in AD patients. The secondary objective is to verify whether peripheral metabolite(s) with potential neuroactive properties can effectively cross the blood-brain barrier (brain metabolome). The third objective is to state a hypothesis about the origin of neuroactive metabolite(s).
Task 1.1: Untargeted metabolomics analysis in the blood of AD patients to identify potential neuroactive metabolite(s) associated with mood disorders
Task 1.2: Untargeted metabolomics analysis in the blood of AD patients to identify potential neuroactive metabolite(s) associated with cognitive functions and brain alterations.
Task 1.3: Measurement of the selected metabolite(s) in the brain and CSF of AD patients, as a reflect of its/their ability to cross the blood-brain barrier
Task 1.4: Identification of the origin of neuroactive metabolite(s)